NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 14 December 2022, 09:30am

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Professor Iolo Doull Present for items 1 to 6.1.3
4. Professor Francis Drobniewski Present for all items
5. Dr Mark Glover Present for all items
6. Dr Bushra Hasnie Present for all items
7. Dr Veline L’Esperance Present for all items
8. Professor Nicholas Latimer Present for all items
9. Professor David McAllister Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers  Present for all items
12. Professor Nicky Welton Present for all items
13. Nigel Westwood Present for all items
14. Peter Wheatley-Price Present for all items
15. Dr Stuart Williams Present for all items
16. Tony Wootton Present for all items

NICE staff (key players) present

Richard Diaz, Associate Director Present for all items

Daniel Davies, Project Manager Present for items 1 to 4.2.2 and 6 to 6.2.1

Jeremy Powell, Project Manager Present for items 5 to 5.3.2

Lorna Dunning, Heath Technology Assessment Adviser Present for items 1 to 4.2.2

Sam Slayen, Heath Technology Assessment Analyst Present for items 1 to 4.2.2

Philip Williams, Business Analyst, RIA Present for all items

Rufaro Kausi, Health Technology Assessment Adviser Present for items 5 to 5.3.2

Vicky Gillis-Elliot, Heath Technology Assessment Analyst Present for items 5 to 5.3.2

Emma Douch, Heath Technology Assessment Analyst Present for items 6 to 6.3.2

Emilene Coventry, Senior Medical Editor Present for items 5 to 5.3.2

Ruth Melville, Senior Medical Editor Present for items 6 to 6.3.2

Carl Jackson, Assistant Project Manager, COT Present for all items

Laura Kelly, Assistant Project Manager, COT Present for items 6 to 6.3.2

Mandy Tonkinson, Public Involvement Adviser, PIP Present for items 6 to 6.3.2

Rosalee Mason, Coordinator, Corporate Office Present for all items

Wajeeha Asim, Administrator, TA Present for all items

Ayla Hudson, Apprentice, Planning and Ops Present for items 5 to 5.3.2

NICE staff (observers) present

Ian Watson, Senior Technical Adviser - Methods and Processes Present for items 5 to 5.3.2

Carl Prescott, Technical Adviser Present for items 1 to 5.3.2

Alan Ashworth, Consultant Clinical Adviser Present for all items

Stephen Norton, Technical Adviser, Managed Access Present for items 5 to 5.3.2

Thomas Palmer, Technical Analyst, Managed Access Present for items 5 to 5.3.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment Present for items 5 to 5.3.2

Denise Moyo, Coordinator, COT Present for items 1 to 6.2.1

Ewa Rupniewska, Health Technology Assessment Adviser Present for items 5 to 5.3.2

Sarah Wilkes, Heath Technology Assessment Analyst Present for items 5.1.3 to 5.3.2

External assessment group representatives present

Graham Scotland, Aberdeen HTA Group Present for items 1 to 4.1.3

Mariana Bacelar, BMJ Group Present for items 5 to 5.2.1

Charlotta Karner, BMJ Group Present for items 5 to 5.2.1

Robert Wolff, Kleijnen Systematic Reviews (KSR) Present for items 6 to 6.2.1

Thea van Asselt, Kleijnen Systematic Reviews (KSR) Present for items 6 to 6.2.1

Clinical, Patient & NHS England experts present

David Chandler, CEO, patient expert nominated by Psoriasis and Psoriatic Arthritis Alliance (PAPAA), present for items 1 to 4.1.3

Helen McAteer, CEO, patient expert nominated by Psoriasis Association, present for items 1 to 4.1.3

Dr Kave Shams, Consultant Dermatologist, clinical expert nominated by University of Leeds, present for items 1 to 4.1.3

Sanjeev Patel, Clinical Advisor, NHS expert nominated by NHS England, present for items 5 to 5.3.2

Will Irving, Professor and Honorary Consultant in Virology, clinical expert nominated by University of Nottingham and Nottingham University Hospitals NHS Trust, present for items 5 to 5.1.3

Lisa Suchet, Trustee/parent/carer, patient expert nominated by Tuberous Sclerosis Association, present for items 6 to 6.1.3

Dr Pooja Takhar, Head of Research and Policy, patient expert nominated by Tuberous Sclerosis Association, present for items 6 to 6.1.3

Sam Amin, Lead Consultant Paediatric Neurologist, clinical expert nominated by University Hospitals Bristol and Weston NHS Foundation Trust, present for items 6 to 6.1.3

Rhys Thomas, Clinical Senior Lecturer / Honorary Neurologist, clinical expert nominated by Newcastle University present for items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The vice chair welcomed members of the committee and other attendees present to the meeting.
  2. The vice chair noted apologies from Dr Hatim Abdulhussein, Maria Bretzitski, Mary Weatherstone, Dr Rhiannon Owen, and Dr Toby Smith.

### News and announcements

* 1. The vice chair stated that this was Professor Nicholas Latimer’s last meeting .

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 10 November 2022.

1. **Appraisal of Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]**
   1. Part 1 – Open session
      1. The vice chair welcomed the invited experts, external assessment group representatives, and company representatives from Bristol Myers Squibb.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Prior to the meeting, Professor Nick Latimer declared a non-financial professional and personal interest as he is a member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme (MSD). This is not drug or appraisal specific and is about developing methods. MSD are listed as a comparator company. It was agreed that his declaration would not prevent Professor Latimer from participating in discussions on this appraisal.
* Prior to the meeting, Professor David McAllister declared a non-financial professional and personal interest as he performs secondary analysis of trial data which was provided by sponsors (or their competitors) via the Vivli, CSDR and YODA trial platforms. It was agreed that his/her declaration would not prevent Professor McAllister from participating in discussions on this appraisal.
* Prior to the meeting, Peter Wheatley-Price declared a direct financial interest as Takeda have Soticlestat, (TAK-935) in phase III trials to treat rare developmental and epileptic encephalopathies (DEE) including Dravet syndrome and Lennox-Gastaut Syndrome. Soticlestat will be a direct competitor to cannibidiol in Dravet & LGS, to his knowledge there are no investigational trials in this specific indication. It was agreed that his declaration would not prevent Peter Wheatley-Price from participating in discussions on this appraisal.
* Helen McAteer declared an indirect financial interest Psoriasis Association has received core fundings from Bristol Myers Squibb and comparator manufacturers such as Abbvie, Almirral, Amgen, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB. It was agreed that her declaration would not prevent Helen McAteer from providing expert advice to the committee.
* Dr Kave Shams declared a direct financial interest as he has received honoraria for advisory boards and educational provision aswell as research funding from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Novartis, Amgen, Biogen, UCB, Boehringer-Ingelheim and Sandoz. Dr Kave Shams is also an investigator for Abbvie, Novartis, UCB, BMS, Janssen, Celgene It was agreed that his declaration would not prevent Dr Kave Shams from providing expert advice to the committee.
* David Chandler declared a non-financial professional and personal interest, as he was a previous member of a NICE Technology Appraisal Committee and is currently a member of the NICE Appeals Committee. It was agreed that his declaration would not prevent David Chandler from providing expert advice to the committee.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Stuart Williams (Clinical) Professor Nicky Welton (Cost) and Nigel Westwood (Lay).
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta10855>

1. **Appraisal of Bulevirtide for treating chronic hepatitis D [ID3732]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Professor David McAllister declared a non-financial professional and personal interest as he performs secondary analysis of trial data which was provided by sponsors (or their competitors) via the Vivli, CSDR and YODA trial platforms. It was agreed that his declaration would not prevent Professor McAllister from participating in discussions on this appraisal.
* Will Irving declared a direct financial interest, as he is supported by a Gilead funded grant to review the epidemiology delta variant of SARS-CoV-2. It was agreed that his/her declaration would not prevent Will Irving from providing expert advice to the committee.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair.
  1. Part 2a – Closed session (members of the public, company representatives and clinical experts were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives and NHS experts were asked to leave the meeting).
     1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10652>

1. **Appraisal of Cannabidiol for treating seizures caused by tuberous sclerosis complex [ID1416]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from GW Pharmaceuticals/Jazz.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Prior to the meeting, Peter Wheatley-Price declared direct financial interests as he is employed by Takeda who have Soticlestat, (TAK-935) in phase III trials to treat rare developmental and epileptic encephalopathies (DEE) including Dravet syndrome and Lennox-Gastaut Syndrome. Soticlestat will be a direct competitor to cannibidiol in Dravet & LGS, to his knowledge there are no investigational trials in this specific indication. It was agreed that his declaration would not prevent Peter Wheatley-Price from participating in discussions on this appraisal.
* Prior to the meeting, Professor David McAllister declared direct a non-financial professional and personal interest as he performs secondary analysis of trial data which was provided by sponsors (or their competitors) via the Vivli, CSDR and YODA trial platforms. It was agreed that his declaration would not prevent Professor McAllister from participating in discussions on this appraisal.
* Prior to the meeting, Dr Pooja Takhar declared direct financial interests, as he is employed by Tuberous Sclerosis Association (TSA) who received a payment of £300 for his time as TSA Head of Research to give an overview of the charity’s work to GW Pharma staff and to take part in a panel Q&A about TSC (as per TSA declaration as nominating organisation). He is also listed as a co-author on two unpublished papers setting out the findings from an online QoL survey about impact of TSC on carers organised by GW Pharma Ltd. Dr Takhar also declared an indirect financial interest as TSA have received funding from GW/Jazz Pharma Ltd and Novartis in the last 12 months. It was agreed that his declaration would not prevent Dr Takhar from providing expert advice to the committee.
* Rhys Thomas declared a direct financial interest, as he receives funding for speaking for a drug companies such as GW Pharmaceuticals/Jazz. He is also a trustee for Epilepsy Research UK, aswell as being a member of the board and treasurer for the British Branch of the International League Against Epilepsy. It was agreed that his declaration would not prevent Rhys Thomas from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair.
  1. Part 2a – Closed session (members of the public, company representatives, clinical and patient experts were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives and were asked to leave the meeting)
     1. The committee then agreed on the Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta10840>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 12 January 2023 and will start promptly at 09:30.